DRRX Share Price

Open 1.27 Change Price %
High 1.40 1 Day 0.09 6.98
Low 1.25 1 Week 0.13 10.40
Close 1.38 1 Month 0.13 10.40
Volume 1132503 1 Year -0.77 -35.81
52 Week High 2.37
52 Week Low 0.99
DRRX Important Levels
Resistance 2 1.52
Resistance 1 1.46
Pivot 1.34
Support 1 1.30
Support 2 1.24
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Durect Corporation (NASDAQ: DRRX)

DRRX Technical Analysis 3
As on 8th Dec 2016 DRRX Share Price closed @ 1.38 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.37 & Buy for SHORT-TERM with Stoploss of 1.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
DRRX Target for December
1st Target up-side 1.5
2nd Target up-side 1.63
3rd Target up-side 1.76
1st Target down-side 1.12
2nd Target down-side 0.99
3rd Target down-side 0.86
DRRX Other Details
Segment EQ
Market Capital 87659144.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.durect.com
DRRX Address
DRRX
10260 Bubb Road
Cupertino, CA 95014
United States
Phone: 408-777-1417
Fax: 408-777-3577
Interactive Technical Analysis Chart Durect Corporation ( DRRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Durect Corporation
DRRX Business Profile
Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company�s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company�s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.